Compare Enveric Biosciences Inc (ENVB) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs PulteGroup, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while PulteGroup, Inc. trades at $113.37 (market cap $21.63B). The key difference: PulteGroup, Inc. is far larger — about 3180.9× Enveric Biosciences Inc's market cap, and PulteGroup, Inc. pays a 0.92% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and PulteGroup, Inc. for 91 Days on average.
| ENVB | PHM | |
|---|---|---|
Market Cap | $6.80M | $21.63B |
Volume | 64,867 | 2,324,729 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $142.56 |
52-Week Low | $1.27 | $110.11 |
Typical Hold Time | 14 Days | 91 Days |
Enterprise Value | -$1.49M | $22.04B |
Dividend Yield | — | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
PulteGroup (PHM) trades at $112.33, down 3.25% amid broader housing sector pressure from rising mortgage rates. The stock shows bearish technical signals with recent earnings misses but maintains solid fundamentals including an 11.47 P/E ratio and 14.9% ROE. Cash flow remains positive at $355 million for 2025, though revenue and margins have softened from 2024 peaks. The company continues dividend payments with a $0.26 quarterly payout scheduled for October 2026.
PHM presents a mixed outlook with attractive valuation metrics offset by near-term headwinds. The consensus price target of $139.80 suggests 24% upside potential, but rising interest rates pose significant risk to housing demand. Investors face tension between Wall Street's bullish price targets and current technical weakness, requiring careful monitoring of Q3 2026 earnings due October 22nd for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
